Search company, investor...
Athenex company logo


Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Athenex

Athenex (NASDAQ: ATNX) is a global oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. It was formerly known as Kinex Pharmaceuticals and QuaDPharma. It was founded in 2003 and is based in Buffalo, New York.

Headquarters Location

1001 Main Street Suite 600

Buffalo, New York, 14203,

United States


Missing: Athenex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Athenex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Athenex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Athenex is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Athenex Patents

Athenex has filed 39 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Signal transduction
  • G protein coupled receptors
patents chart

Application Date

Grant Date


Related Topics




Epidermal nevi, neoplasms, cysts, Surgical removal procedures, Oral mucosal pathology, Conditions of the mucous membranes, Genodermatoses


Application Date


Grant Date



Related Topics

Epidermal nevi, neoplasms, cysts, Surgical removal procedures, Oral mucosal pathology, Conditions of the mucous membranes, Genodermatoses



Latest Athenex News

Europe Compounding Pharmacies Market Report 2023: Sector to Grow by 8.25% Annually Through 2028 -

Jan 9, 2023

January 09, 2023 10:41 AM Eastern Standard Time The European Compounding Pharmacies Market is projected to display significant growth represented by a CAGR of 8.25% during 2023-2028. The European Compounding Pharmacies Market was valued at USD 3314.80 Million in the year 2021 with Italy holding the largest market share. In terms of segments, the availability of a diverse range of compounded formulas for dermatological purposes will drive segment expansion. Patients who are allergic to commercial pharmaceuticals might benefit from dermatology customised treatments. The European Compounding Pharmacies market is a consolidated market. The major players in the market like Athenex, Baxter International, Fagron, Grifols, Capsa Healthcare, Nephron Pharmaceuticals, B. Braun, Fresenius, McKesson and Omnicell have a large geographical presence and a highly diversified product portfolio. These players focus on R&D, a large product portfolio, a wide geographical presence and an aggressive acquisition strategy. Italy is holding the largest market share and is growing at the fastest rate during the forecast period, owing to the rising prevalence of therapeutic areas as well as the widespread use of pain management in developed countries like the United Kingdom and Germany. The United Kingdom Compounding Pharmacies market has witnessed growth in recent years due to increased investments and offtake agreements among new companies to cope with new market strategies. France is a lucrative market because of the presence of several compounding pharmacies, high adoption among people, and scarcity of many drugs, which are key factors for market growth. Scope of the Report The report analyses the Europe Compounding Pharmacies Market by Value (USD Million). The report analyses the Europe Compounding Pharmacies by Therapeutic Area (Hormone Replacement, Pain Management, Dermatology, and Other Sources). The report analyses the Europe Compounding Pharmacies Market), by End Users (Adult, Pediatric, Others, Geriatric, Veterinary). The report analyses the Europe Compounding Pharmacies Market by Type (Oral, Topical, Ophthalmic, Injecs, and Others Types). The Europe Compounding Pharmacies Market has been analysed by Country (United Kingdom, Germany, France, Italy, Spain, Russia, Turkey, Benelux, Nordic, and Rest of Europe). The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by country, by Therapeutic Area, by End Users, by Type. Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report. The report tracks competitive developments, strategies, and recent developments. The companies analysed in the report include Athenex, Baxter International, Fagron, Grifols, Capsa Healthcare, Nephron Pharmaceuticals, B. Braun, Fresenius, McKesson and Omnicell. The report presents the analysis of the European Compounding Pharmacies Market for the historical period of 2018-2021, the estimated year 2022 and the forecast period of 2023-2028. Key Target Audience Government Bodies & Regulating Authorities 7. Macro Economic Indicator Outlook 8. Europe compounding Pharmacies Market 9. Europe Compounding Pharmacies Market Trend And Forecast Analysis, 2018-2028, By Therapeutic Area 10. Europe Compounding Pharmacies Market Trend And Forecast Analysis, 2018-2028, By End Users 11. Europe Compounding Pharmacies Market Trend And Forecast Analysis, 2018-2028, By Type 12. Europe Compounding Pharmacies Market Trend And Forecast Analysis, 2018-2028, By Country 13. Competitive Positioning About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contacts

Athenex Frequently Asked Questions (FAQ)

  • When was Athenex founded?

    Athenex was founded in 2003.

  • Where is Athenex's headquarters?

    Athenex's headquarters is located at 1001 Main Street, Buffalo.

  • What is Athenex's latest funding round?

    Athenex's latest funding round is IPO.

  • How much did Athenex raise?

    Athenex raised a total of $131.97M.

  • Who are the investors of Athenex?

    Investors of Athenex include Huateng Ma, Advantage Capital, Rand Capital, Pharminex, Manson Fok and 4 more.

  • Who are Athenex's competitors?

    Competitors of Athenex include Radius, Aegerion Pharmaceuticals, Viamet Pharmaceuticals, Acetylon Pharmaceuticals, Neuraltus Pharmaceuticals and 13 more.

Compare Athenex to Competitors

Alvine Pharmaceuticals

Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.

Radius Logo

Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Funxional Therapeutics

Funxional Therapeutics Ltd.'s focus is on broad-spectrum chemokine inhibitors. Its small molecule lead candidate has entered clinical development. The chemokine inhibitors will target a broad range of inflammatory conditions.

Verus Pharmaceuticals

Verus Pharmaceuticals is developing products treating asthma


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.